

Author Index (Vol. 69)

Adams, C.W.M., see Keohane, S.G., 103
Albers, J.J., see Miller, N.E., 123
Amy, R.M., Dolphin, P.J., Pederson, R.A. and Russell, J.C., Atherogenesis in two strains of obese rats. The fatty Zucker and LA/N-corpulent, 199
Aoyama, H., Mori, N. and Mori, W., Effects of melatonin on genetic hypercholesterolemia in rats, 269
Aursnes, I., Smith, P., Christiansen, E.N., and Berg, K., Factor analysis of plasma lipoprotein components, 219
Avogaro, P., Cazzolato, G. and Bittolo Bon, G., A question concerning apo B-48 (Letter to the Editor), 273

Ball, M., see Jenner, K., 39
Baralle, F.E., see Jenner, K., 39
Baskerville, P., see Shaikh, M., 165
Berg, K., see Aursnes, I., 219
Berguer, R., see Kessel, D., 1
Bittolo Bon, G., see Avogaro, P., 273
Bowyer, D.E., see Jackson, C.L., 115
Brown, W.E., see Tomazic, B.B., 5
Browse, N.L., see Shaikh, M., 165
Bujo, H., see Saito, Y., 161
Bush, R.C., see Jackson, C.L., 115

Caslake, M.J., see Series, J.J., 233
Cazzolato, G., see Avogaro, P., 273
Christiansen, E.N., see Aursnes, I., 219
Cremer, P., see Siegrist, J., 211
Cruickshank, A., see Series, J.J., 233
Czekelius, P., see Steinmetz, A., 21

Delcroix, C., see Malmendier, C.L., 51
Demacker, P.N.M., Hijmans, A.G.M., Stalenhoef, A.F.H. and Van't Laar, A., Studies on the function of hepatic lipase in the cat after immunological blockade of the enzyme in vivo, 173
Demand, T., see Series, J.J., 233
Diehl, A.K., Fuller, J.H., Mattock, M.B., Salter, A.M., El-Gohari, R. and Keen, H., The relationship of high density lipoprotein subfractions to alcohol consumption, other lifestyle factors, and coronary heart disease, 145
Dolphin, P.J., see Amy, R.M., 199
Duffield, R., see Shaikh, M., 165

El-Gohari, R., see Diehl, A.K., 145
Erkelens, D.W., see Mol, M.J.T.M., 131

Faris, B., see Ohishi, H., 61
Fears, R., Ferres, H., Haacke, H., Mäder, C. and Parwaresch, M.R., Decrease in LDL and increase in HDL concentrations in type II hyperlipoproteinemic patients on low-dose combination therapy of cholestyramine and Complamin®, 97
Ferres, H., see Fears, R., 97
Franzblau, C., see Ohishi, H., 61
Franzblau, C., see Schreiber, B.M., 69
Friedlander, Y., see Simons, L.A., 139
Fuller, J.H., see Diehl, A.K., 145

Gevers Leuven, J.A., see Mol, M.J.T.M., 131
Giudici, G., see Jenner, K., 39
Grab, B., see Hong, M.L., 241
Grutman, G.A., see Malmendier, C.L., 51

Haacke, H., see Fears, R., 97
Hausmann, J., see Ohishi, H., 61
Hess, D., see Ohishi, H., 61
Hijmans, A.G.M., see Demacker, P.N.M., 173
Hollander, W., see Schreiber, B.M., 69
Hong, M.L., James, R.W., Grab, B. and Pometta, D., High density lipoprotein (HDL) subfractions in cardiovascular patients with low levels of HDL-cholesterol. Influence of hyperglyceridemia on subfraction concentration and composition, 241
Hüther, A.M., see Rücker, W., 155

Jaakkola, O., Kallioniemi, O.-P. and Nikkari, T., Lipoprotein uptake in primary cell cultures of rabbit atherosclerotic lesions. A fluorescence microscopic and flow cytometric study, 257
Jackson, C.L., Bush, R.C. and Bowyer, D.E., Inhibitory effect of calcium antagonists on balloon catheter-induced arterial smooth muscle cell proliferation and lesion size, 115
James, R.W., see Hong, M.L., 241
Jenner, K., Sidoli, A., Ball, M., Rodriguez, J.R., Pagani, F., Giudici, G., Vergani, C., Mann, J., Baralle, F.E. and Shoulders, C.C., Characterization of genetic markers in the 3' end of the apo B gene and their use in family and population studies, 39

Kaffarnik, H., see Steinmetz, A., 21
Kallioniemi, O.-P., see Jaakkola, O., 257
Kark, J.D., see Simons, L.A., 139
Keen, H., see Diehl, A.K., 145

Keohane, S.G., Adams, C.W.M. and Poston, R.N., Coronary arterial dimensions and cell populations in ageing man, 103

Kessel, D. and Berguer, R., Determinants of porphyrin fluorescence emission spectra of atheromatous plaques, 1

Kilday, C., see Series, J.J., 233

Klurfeld, D.M., see Kritchevsky, D., 89

Kobori, S., Nakamura, N., Uzawa, H. and Shichiri, M., Influence of apolipoprotein E polymorphism on plasma lipid and apolipoprotein levels, and clinical characteristics of type III hyperlipoproteinemia due to apolipoprotein E phenotype E2/2 in Japan, 81

Kosakai, M., see Ohishi, H., 61

Kritchevsky, D., Tepper, S.A. and Klurfeld, D.M., Flordipine, a calcium channel blocker, which does not influence lipidemia or atherosclerosis in cholesterol-fed rabbits (Preliminary Note), 89

Kuusi, T., see Sorva, R., 191

La Ville, A.E., see Shaikh, M., 165

Lewis, B., see Shaikh, M., 165

Lontie, J.-F., see Malmendier, C.L., 51

Madeo, Y., see Mainard, F., 225

Mäder, C., see Fears, R., 97

Mainard, F., Ozanne, P. and Madeo, Y., Variations in lipoproteins, hormones and blood glucose during the early acute phase of myocardial infarction, 225

Malmendier, C.L., Lontie, J.-F., Grutman, G.A. and Delcroix, C., Metabolism of apolipoprotein C-III in normolipemic human subjects, 51

Mann, J., see Jenner, K., 39

Martin, B.M., see Schreiber, B.M., 69

Martini, S., see Shaikh, M., 165

Matschinger, H., see Siegrist, J., 211

Mattock, M.B., see Diehl, A.K., 145

Miller, N.E., Rajput-Williams, J., Nanjee, M.N., Samuel, L. and Albers, J.J., Relationship of high density lipoprotein composition to plasma lecithin : cholesterol acyltransferase concentration in men, 123

Mogayzel, Jr., P.J., see Ohishi, H., 61

Mol, M.J.T.M., Erkelen, D.W., Gevers Leuven, J.A., Schouten, J.A. and Stalenhoef, A.F.H., Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolemia, 131

Mori, N., see Aoyama, H., 269

Mori, W., see Aoyama, H., 269

Morisaki, N., see Saito, Y., 161

Motzny, S., see Steinmetz, A., 21

Nakamura, N., see Kobori, S., 81

Nanjee, M.N., see Miller, N.E., 123

Nikkari, T., see Jaakkola, O., 257

Nikkilä, E.A., see Sorva, R., 191

Nikkilä, E.A., see Taskinen, M.-R., 249

Ohishi, H., Hess, D., Kosakai, M., Schmid, K., Hausmann, J., Mogayzel, Jr., P.J., Faris, B. and Franzblau, C., Glycosaminoglycan content in neonatal rat aortic smooth muscle cell cultures, 61

Olpin, S.E. and Price, C.P., High density lipoprotein and apolipoprotein A-I in acute phase response (letter to the Editor), 93

Olszewski, A.J. and Szostak, W.B., Homocysteine content of plasma proteins in ischemic heart disease, 109

Ozanne, P., see Mainard, F., 225

Packard, C.J., see Series, J.J., 233

Pagani, F., see Jenner, K., 39

Parwaresch, M.R., see Fears, R., 97

Patsch, W., see Tamai, T., 29

Pederson, R.A., see Amy, R.M., 199

Perheentupa, J., see Sorva, R., 191

Poapst, M., Uffelman, K. and Steiner, G., A question concerning apo B-48: A reply to the letter by P. Avogaro, G.G. Gazzalato and G. Bittolo Bon (Letter to the Editor), 275

Pometta, D., see Hong, M.L., 241

Poston, R.N., see Keohane, S.G., 103

Price, C.P., see Olpin, S.E., 93

Prop, G., see Rücker, W., 155

Queral, L.A., see Tomazic, B.B., 5

Quiney, J.R., see Shaikh, M., 165

Rajput-Williams, J., see Miller, N.E., 123

Rodriguez, J.R., see Jenner, K., 39

Russell, J.C., see Amy, R.M., 199

Rücker, W., Prop, G. and Hüther, A.M., Antiatherosclerotic and antihyperlipidemic effects of octimibate sodium in rabbits, 155

Sachinidis, A., see Zidek, W., 185

Sadovnik, M., see Tomazic, B.B., 5

Saito, Y., Bujo, H., Morisaki, N., Shirai, K. and Yoshida, S., Proliferation and LDL binding of cultured intimal smooth muscle cells from rabbits, 161

Salter, A.M., see Diehl, A.K., 145

Samuel, L., see Miller, N.E., 123

Schmid, K., see Ohishi, H., 61

Schonfeld, G., see Tamai, T., 29

Schouten, J.A., see Mol, M.J.T.M., 131

Schreiber, B.M., Martin, B.M., Hollander, W. and Franzblau, C., β -VLDL-induced alterations in growth potentiating activity produced by mononuclear phagocytes, 69

Seidel, D., see Siegrist, J., 211

Series, J.J., Caslake, M.J., Kilday, C., Cruickshank, A., Demant, T., Packard, C.J. and Shepherd, J., Influence of etofibrate on low density lipoprotein metabolism, 233

Shaike, M., Martini, S., Quiney, J.E., Baskerville, P., La Ville, A.E., Browne, N.L., Duffield, R., Turner, P.R. and Lewis, B., Modified plasma-derived lipoproteins in human atherosclerotic plaques, 165

Shepherd, J., see Series, J.J., 233

Shichiri, M., see Kobori, S., 81

Shirai, K., see Saito, Y., 161

Shoulders, C.C., see Jenner, K., 39

Sidoli, A., see Jenner, K., 39

Siegrist, J., Matschinger, H., Cremer, P. and Seidel, D., Atherogenic risk in men suffering from occupational stress, 211

Simons, J., see Simons, L.A., 139

Simons, L.A., Friedlander, Y., Simons, J. and Kark, J.D., Familial aggregation of coronary heart disease: partial mediation by high density lipoproteins?, 139

Smith, P., see Aursnes, I., 219

Sorva, R., Kuusi, T., Taskinen, M.-R., Perheentupa, J. and Nikkilä, E.A., Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males, 191

Spieker, C., see Zidek, W., 185

Stalenhoef, A.F.H., see Demacker, P.N.M., 173

Stalenhoef, A.F.H., see Mol, M.J.T.M., 131

Steiner, G., see Poapst, M., 275

Steinmetz, A., Czekelius, P., Thiemann, E., Motzny, S. and Kaffarnik, H., Changes of apolipoprotein A-IV in the human neonate: evidence for different inductions of apolipoproteins A-IV and A-I in the postpartum period, 21

Storkebaum, W., see Zidek, W., 185

Szostak, W.B., see Olszewski, A.J., 109

Tamai, T., Patsch, W. and Schonfeld, G., Regulation of lipoprotein receptors on a rat hepatoma cell line, 29

Taskinen, M.-R. and Nikkilä, E.A., Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia, 249

Taskinen, M.-R., see Sorva, R., 191

Tepper, S.A., see Kritchevsky, D., 89

Thiemann, E., see Steinmetz, A., 21

Tomazic, B.B., Brown, W.E., Queral, L.A. and Sadovnik, M., Physicochemical characterization of cardiovascular calcified deposits. I. Isolation, purification and instrumental analysis, 5

Turner, P.R., see Shaikh, M., 165

Uffelman, K., see Poapst, M., 275

Uzawa, H., see Kobori, S., 81

Van 't Laar, A., see Demacker, P.N.M., 173

Vergani, C., see Jenner, K., 39

Yoshida, S., see Saito, Y., 161

Zidek, W., Sachinidis, A., Spieker, C. and Storkebaum, W., Effect of hypertensive plasma on Ca^{2+} transport in human neutrophils, 185

Subject Index (Vol. 69)

ACAT inhibitor
-, Atherosclerosis; Rabbits; Cholesterol-rich diet; Octimibate sodium, 155

Acetylated LDL
-, Atherosclerosis; Cell proliferation; Foam cell; Intimal smooth muscle cells; LDL, 161
-, Atherosclerosis; Fluorescently labelled lipoproteins; LDL; Macrophages; Smooth muscle cells, 257

Acipimox
-, Lipoproteins; HDL; Lipolytic enzymes; Hypertriglyceridemia, 249

Ageing
-, Arteritis; Atherosclerosis; Coronary artery; Image analysis; Lymphocyte, 103

Alcohol
-, Lipoproteins; HDL subfractions; Obesity; Coronary heart disease, 145

α -Amino adipic acid
-, Atherosclerosis; Homocysteine; Human plasma; Homocysteine-cysteine mixed disulfide, 109

Animal model
-, Hepatic triglyceride lipase; Chylomicrons; Lipoproteins; Postprandial phase; Apoproteins, 173

Antihypercholesterolemic effect
-, Melatonin; Genetically hypercholesterolemic rat, 269

Antihypertensive agents
-, Calcium antagonists; Balloon catheter; Smooth muscle cell proliferation; Nifedipine, 115

Aortic smooth muscle cell cultures (rat)
-, Glycosaminoglycans; Ascorbate, 61

Apo A-I
-, HDL subfractions; Hypertriglyceridemia; Cardiovascular patients; Apo A-II, 241

Apo A-II
-, HDL subfractions; Hypertriglyceridemia; Cardiovascular patients; Apo A-I, 241

Apo B genetic markers
-, Hyperlipidemia; Hypervariable region, 39

Apolipoprotein(s)
-, Apolipoprotein E polymorphism; Lipids; Hyperlipoproteinemia type III, 81
-, Atherosclerosis; Cholesterol; Factor analysis; Fatty acids; Lipoproteins; Triglycerides, 219
-, Familial hypercholesterolemia; Cholesterol; Hydroxymethylglutaryl-coenzyme A reductase; Lipoproteins, 131
Apolipoproteins, *see also under* Apo

Apolipoprotein C-III turnover
-, Lipoprotein fractions; Metabolism; Normal subjects; In vivo kinetics; Plasma; Urine; Bolton-Hunter labeling; Iodine monochloride labeling, 51

Apolipoprotein E polymorphism
-, Lipids; Apolipoproteins; Hyperlipoproteinemia type III, 81

Apolipoprotein polymorphism
-, Immunoblotting; Umbilical cord apoproteins; Fat absorption, 21

Apoprotein(s)
-, Arterial lipoproteins; Macrophages; Scavenger receptor, 165
-, Hepatic triglyceride lipase; Animal model; Chylomicrons; Lipoproteins; Postprandial phase, 173
-, Myocardial infarction; Lipids; Lipoproteins; Blood glucose; Insulin; Cortisol; Vanillylmandelic acid, 225
-, Testosterone; HDL-cholesterol; Hepatic lipase; Lipoprotein lipase, 191

Arterial lipoprotein(s)
-, Apoproteins; Macrophages; Scavenger receptor, 165

Arteritis
-, Ageing; Atherosclerosis; Coronary artery; Image analysis; Lymphocyte, 103

Ascorbate
-, Aortic smooth muscle cell cultures (rat); Glycosaminoglycans, 61

Atherogenic risk
-, Ratio between LDL and HDL; Job insecurity; Shift work, 211

Atheromatous plaques
-, LDL; Porphyrins, 1

Atherosclerosis
-, Acetylated LDL; Fluorescently labelled lipoproteins; LDL; Macrophages; Smooth muscle cells, 257
-, Ageing; Arteritis; Coronary artery; Image analysis; Lymphocyte, 103
-, α -Amino adipic acid; Homocysteine; Human plasma; Homocysteine-cysteine mixed disulfide, 109
-, Apolipoproteins; Cholesterol; Factor analysis; Fatty acids; Lipoproteins; Triglycerides, 219
-, Calcium channel blockers; Cholesterol; Flordipine; Liver lipids; Serum lipids, 89
-, Cell proliferation; Foam cell; Intimal smooth muscle cells; LDL; Acetylated LDL, 161
-, Growth potentiating activity; Mononuclear phagocytes; Foam cells; β -VLDL, 69
-, Hyperlipidemia; Hyperinsulinemia; Myocardial lesions; Scanning electron microscopy, 199

- , Rabbits; Cholesterol-rich diet; ACAT inhibitor; Octimibe sodium, 155
- Balloon catheter**
 - , Calcium antagonists; Smooth muscle cell proliferation; Nifedipine; Antihypertensive agents, 115
- Blood glucose**
 - , Myocardial infarction; Lipids; Lipoproteins; Apoproteins; Insulin; Cortisol; Vanillylmandelic acid, 225
- Bolton-Hunter labeling**
 - , Apolipoprotein C-III turnover; Lipoprotein fractions; Metabolism; Normal subjects; In vivo kinetics; Plasma; Urine; Iodine monochloride labeling, 51
- Calcium antagonists**
 - , Balloon catheter; Smooth muscle cell proliferation; Nifedipine; Antihypertensive agents, 115
- Calcium channel blockers**
 - , Atherosclerosis; Cholesterol; Flordipine; Liver lipids; Serum lipids, 89
- Calcium ion**
 - , Essential hypertension; Neutrophils, 185
- Carbonate apatite**
 - , Cardiovascular mineral; Hydroxyapatite; Octacalcium phosphate; Physicochemical characterization, 5
- Cardiovascular mineral**
 - , Hydroxyapatite; Octacalcium phosphate; Carbonate apatite; Physicochemical characterization, 5
- Cardiovascular patients**
 - , HDL subfractions; Hypertriglyceridemia; Apo A-I; Apo A-II, 241
- Cell density**
 - , Lipoprotein receptor; Regulation; Lipoprotein deficient serum, 29
- Cell proliferation**
 - , Atherosclerosis; Foam cell; Intimal smooth muscle cells; LDL; Acetylated LDL, 161
- Cholesterol**
 - , Apolipoproteins; Atherosclerosis; Factor analysis; Fatty acids; Lipoproteins; Triglycerides, 219
 - , Atherosclerosis; Calcium channel blockers; Flordipine; Liver lipids; Serum lipids, 89
 - , Familial hypercholesterolemia; Hydroxymethylglutaryl-coenzyme A reductase; Lipoprotein; Apolipoprotein, 131
- Cholesterol-rich diet**
 - , Atherosclerosis; Rabbits; ACAT inhibitor; Octimibe sodium, 155
- Cholestyramine**
 - , Complamin®; Combination therapy; Hyperlipoproteinemia; LDL; HDL, 97
- Chylomicrons**
 - , Hepatic triglyceride lipase; Animal model; Lipoproteins; Postprandial phase; Apoproteins, 173
- Combination therapy**
 - , Complamin®, Cholestyramine; Hyperlipoproteinemia; LDL; HDL, 97
- Complamin®**
 - , Cholestyramine; Combination therapy; Hyperlipoproteinemia; LDL; HDL, 97
- Coronary artery**
 - , Ageing; Arteritis; Atherosclerosis; Image analysis; Lymphocyte, 103
- Coronary heart disease**
 - , Family history; HDL-cholesterol; Cross-sectional study, 139
 - , Lipoproteins, HDL subfractions; Alcohol; Obesity, 145
- Cortisol**
 - , Myocardial infarction; Lipids; Lipoproteins; Apoproteins; Blood glucose; Insulin; Vanillylmandelic acid, 225
- Cross-sectional study**
 - , Coronary heart disease; Family history; HDL-cholesterol, 139
- Essential hypertension**
 - , Calcium ion; Neutrophils, 185
- Factor analysis**
 - , Apolipoproteins; Atherosclerosis; Cholesterol; Fatty acids; Lipoproteins; Triglycerides, 219
- Familial hypercholesterolemia**
 - , Cholesterol; Hydroxymethylglutaryl-coenzyme A reductase; Lipoprotein; Apolipoprotein, 131
- Family history**
 - , Coronary heart disease; HDL-cholesterol; Cross-sectional study, 139
- Fat absorption**
 - , Apolipoprotein polymorphism; Immunoblotting; Umbilical cord apoproteins, 21
- Fatty acids**
 - , Apolipoproteins; Atherosclerosis; Cholesterol; Factor analysis; Lipoproteins; Triglycerides, 219
- Flordipine**
 - , Atherosclerosis; Calcium channel blockers; Cholesterol; Liver lipids; Serum lipids 89
- Fluorescently labelled lipoproteins**
 - , Acetylated LDL; Atherosclerosis; LDL; Macrophages; Smooth muscle cells, 257
- Foam cell(s)**
 - , Atherosclerosis; Cell proliferation; Intimal smooth muscle cells; LDL; Acetylated LDL, 161
 - , Growth potentiating activity; Mononuclear phagocytes; β -VLDL; Atherosclerosis, 69
- Fractional clearance rate**
 - , LDL catabolism (receptor-mediated and receptor-independent); Synthetic rate; HDL, 233
- Genetically hypercholesterolemic rat**
 - , Melatonin; Antihypercholesterolemic effect, 269
- Glycosaminoglycans**
 - , Aortic smooth muscle cell cultures (rat); Ascorbate, 61
- Growth potentiating activity**
 - , Mononuclear phagocytes; Foam cells; β -VLDL; Atherosclerosis, 69
- HDL**
 - , Complamin®, Cholestyramine; Combination therapy; Hyperlipoproteinemia; LDL, 97
 - , LDL catabolism (receptor-mediated and receptor-independent); Fractional clearance rate; Synthetic rate, 233

- , Plasma lecithin:cholesterol acyltransferase; Plasma concentration; HDL-cholesterol, 123
- HDL-cholesterol
 - , Coronary heart disease; Family history; Cross-sectional study, 139
 - , HDL; Plasma lecithin:cholesterol acyltransferase; Plasma concentration, 123
 - , Testosterone; Apoproteins; Hepatic lipase; Lipoprotein lipase, 191
- HDL subfractions
 - , Hypertriglyceridemia; Cardiovascular patients; Apo A-I; Apo A-II, 241
 - , Lipoproteins; Alcohol; Obesity; Coronary heart disease, 145
- Hepatic lipase
 - , Testosterone; HDL-cholesterol; Apoproteins; Lipoprotein lipase, 191
- Hepatic triglyceride lipase
 - , Animal model; Chylomicrons; Lipoproteins; Postprandial phase; Apoproteins, 173
- High density lipoproteins, *see also under HDL*
- Homocysteine
 - , α -Amino adipic acid; Atherosclerosis; Human plasma; Homocysteine-cysteine mixed disulfide, 109
 - Homocysteine-cysteine mixed disulfide
 - , α -Amino adipic acid; Atherosclerosis; Homocysteine; Human plasma, 109
- Human plasma
 - , α -Amino adipic acid; Atherosclerosis; Homocysteine; Homocysteine-cysteine mixed disulfide, 109
- Hydroxyapatite
 - , Cardiovascular mineral; Octacalcium phosphate; Carbonate apatite; Physicochemical characterization, 5
- Hydroxymethylglutaryl-coenzyme A reductase
 - , Familial hypercholesterolemia; Cholesterol; Lipoprotein; Apolipoprotein, 131
- Hyperinsulinemia
 - , Atherosclerosis; Hyperlipidemia; Myocardial lesions; Scanning electron microscopy, 199
- Hyperlipidemia
 - , Apo B genetic markers; Hypervariable region, 39
 - , Atherosclerosis; Hyperinsulinemia; Myocardial lesions; Scanning electron microscopy, 199
- Hyperlipoproteinemia
 - , Complamrin[®]; Cholestyramine; Combination therapy; LDL; HDL, 97
- Hyperlipoproteinemia type III
 - , Apolipoprotein E polymorphism; Lipids; Apolipoproteins, 81
- Hypertriglyceridemia
 - , HDL subfractions; Cardiovascular patients; Apo A-I; Apo A-II, 241
 - , Lipoproteins; HDL; Acipimox; Lipolytic enzymes, 249
- Hypervariable region
 - , Hyperlipidemia; Apo B genetic markers, 39
- Image analysis
 - , Ageing; Arteritis; Atherosclerosis; Coronary artery; Lymphocyte, 103
- Immunoblotting
 - , Apolipoprotein polymorphism; Umbilical cord apoproteins; Fat absorption, 21
- Insulin
 - , Myocardial infarction; Lipids; Lipoproteins; Apoproteins; Blood glucose; Cortisol; Vanillylmandelic acid, 225
- Intimal smooth muscle cells
 - , Atherosclerosis; Cell proliferation; Foam cell; LDL; Acetylated LDL, 161
- In vivo kinetics
 - , Apolipoprotein C-III turnover; Lipoprotein fractions; Metabolism; Normal subjects; Plasma; Urine; Bolton-Hunter labeling; Iodine monochloride labeling, 51
- Iodine monochloride labeling
 - , Apolipoprotein C-III turnover; Lipoprotein fractions; Metabolism; Normal subjects; In vivo kinetics; Plasma; Urine; Bolton-Hunter labeling, 51
- Job insecurity
 - , Atherogenic risk; Ratio between LDL and HDL; Shift work, 211
- LDL
 - , Acetylated LDL; Atherosclerosis; Fluorescently labelled lipoproteins; Macrophages; Smooth muscle cells, 257
 - , Atheromatous plaques; Porphyrins, 1
 - , Atherosclerosis; Cell proliferation; Foam cell; Intimal smooth muscle cells Acetylated LDL, 161
 - , Complamrin[®]; Cholestyramine; Combination therapy; Hyperlipoproteinemia; HDL, 97
- LDL catabolism (receptor-mediated and receptor-independent)
 - , Fractional clearance rate; Synthetic rate; HDL, 233
- Lipids
 - , Apolipoprotein E polymorphism; Apolipoproteins; Hyperlipoproteinemia type III, 81
 - , Myocardial infarction; Lipoproteins; Apoproteins; Blood glucose; Insulin; Cortisol; Vanillylmandelic acid, 225
- Lipolytic enzymes
 - , Lipoproteins; HDL; Acipimox; Hypertriglyceridemia, 249
- Lipoprotein(s)
 - , Apolipoproteins; Atherosclerosis; Cholesterol; Factor analysis; Fatty acids; Triglycerides, 219
 - , Familial hypercholesterolemia; Cholesterol; Hydroxymethylglutaryl-coenzyme A reductase; Apolipoprotein, 131
 - , HDL; Acipimox; Lipolytic enzymes; Hypertriglyceridemia, 249
 - , HDL subfractions; Alcohol; Obesity; Coronary heart disease, 145
 - , Hepatic triglyceride lipase; Animal model; Chylomicrons; Postprandial phase; Apoproteins, 173
 - , Myocardial infarction; Lipids; Apoproteins; Blood glucose; Insulin; Cortisol; Vanillylmandelic acid, 225
- Lipoprotein deficient serum
 - , Lipoprotein receptor; Regulation; Cell density, 29
- Lipoprotein fractions
 - , Apolipoprotein C-III turnover; Metabolism; Normal subjects; In vivo kinetics; Plasma; Urine; Bolton-Hunter labeling; Iodine monochloride labeling, 51

- Lipoprotein lipase**
 - Testosterone; HDL-cholesterol; Apoproteins; Hepatic lipase, 191
- Lipoprotein receptor**
 - Regulation; Cell density; Lipoprotein deficient serum, 29
- Liver lipids**
 - Atherosclerosis; Calcium channel blockers; Cholesterol; Flordipine; Serum lipids, 89
- Low density lipoproteins, *see also under* LDL**
- Lymphocyte**
 - Ageing; Arteritis; Atherosclerosis; Coronary artery; Image analysis, 103
- Macrophages**
 - Acetylated LDL; Atherosclerosis; Fluorescently labelled lipoproteins; LDL; Smooth muscle cells, 257
 - Arterial lipoproteins; Apoproteins; Scavenger receptor, 165
- Melatonin**
 - Genetically hypercholesterolemic rat; Antihypercholesterolemic effect, 269
- Metabolism**
 - Apolipoprotein C-III turnover; Lipoprotein fractions; Normal subjects; In vivo kinetics; Plasma; Urine; Bolton-Hunter labeling; Iodine monochloride labeling, 51
- Mononuclear phagocytes**
 - Growth potentiating activity; Foam cells; β -VLDL; Atherosclerosis, 69
- Myocardial infarction**
 - Lipids; Lipoproteins; Apoproteins; Blood glucose; Insulin; Cortisol; Vanillylmandelic acid, 225
- Myocardial lesions**
 - Atherosclerosis; Hyperlipidemia; Hyperinsulinemia; Scanning electron microscopy, 199
- Neutrophils**
 - Calcium ion; Essential hypertension, 185
- Nifedipine**
 - Calcium antagonists; Balloon catheter; Smooth muscle cell proliferation; Antihypertensive agents, 115
- Normal subjects**
 - Apolipoprotein C-III turnover; Lipoprotein fractions; Metabolism; In vivo kinetics; Plasma; Urine; Bolton-Hunter labeling; Iodine monochloride labeling, 51
- Obesity**
 - Lipoproteins; HDL subfractions; Alcohol; Coronary heart disease, 145
- Octacalcium phosphate**
 - Cardiovascular mineral; Hydroxyapatite; Carbonate apatite; Physicochemical characterization, 5
- Octimibate sodium**
 - Atherosclerosis; Rabbits; Cholesterol-rich diet; ACAT inhibitor, 155
- Physicochemical characterization**
 - Cardiovascular mineral; Hydroxyapatite; Octacalcium phosphate; Carbonate apatite, 5
- Plasma**
 - Apolipoprotein C-III turnover; Lipoprotein fractions; Metabolism; Normal subjects; In vivo kinetics; Urine; Bolton-Hunter labeling; Iodine monochloride labeling, 51
- Plasma concentration**
 - HDL; Plasma lecithin:cholesterol acyltransferase; HDL-cholesterol, 123
- Plasma lecithin:cholesterol acyltransferase**
 - HDL; Plasma concentration; HDL-cholesterol, 123
- Porphyrins**
 - Atheromatous plaques, LDL, 1
- Postprandial phase**
 - Hepatic triglyceride lipase; Animal model; Chylomicrons; Lipoproteins; Apoproteins, 173
- Rabbits**
 - Atherosclerosis; Cholesterol-rich diet; ACAT inhibitor; Octimibate sodium, 155
- Ratio between LDL and HDL**
 - Atherogenic risk; Job insecurity; Shift work, 211
- Regulation**
 - Lipoprotein receptor; Cell density; Lipoprotein deficient serum, 29
- Scanning electron microscopy**
 - Atherosclerosis; Hyperlipidemia; Hyperinsulinemia; Myocardial lesions, 199
- Scavenger receptor**
 - Arterial lipoproteins; Apoproteins; Macrophages, 165
- Serum lipids**
 - Atherosclerosis; Calcium channel blockers; Cholesterol; Flordipine; Liver lipids, 89
- Shift work**
 - Atherogenic risk; Ratio between LDL and HDL; Job insecurity, 211
- Smooth muscle cell(s)**
 - Acetylated LDL; Atherosclerosis; Fluorescently labelled lipoproteins; LDL; Macrophages, 257
- Smooth muscle cell proliferation**
 - Calcium antagonists; Balloon catheter; Nifedipine; Antihypertensive agents, 115
- Synthetic rate**
 - LDL catabolism (receptor-mediated and receptor-independent); Fractional clearance rate; HDL, 233
- Testosterone**
 - HDL-cholesterol; Apoproteins; Hepatic lipase; Lipoprotein lipase, 191
- Triglycerides**
 - Apolipoproteins; Atherosclerosis; Cholesterol; Factor analysis; Fatty acids; Lipoproteins, 219
- Umbilical cord apoproteins**
 - Apolipoprotein polymorphism; Immunoblotting; Fat absorption, 21
- Urine**
 - Apolipoprotein C-III turnover; Lipoprotein fractions; Metabolism; Normal subjects; In vivo kinetics; Plasma; Bolton-Hunter labeling; Iodine monochloride labeling, 51
- Vanillylmandelic acid**
 - Myocardial infarction; Lipids; Lipoproteins; Apoproteins; Blood glucose; Insulin; Cortisol, 225
- Very low density lipoproteins, *see also under* VLDL**
- β -VLDL**
 - Growth potentiating activity; Mononuclear phagocytes; Foam cells; Atherosclerosis, 69

(Contents continued from back cover)

Atherogenic risk in men suffering from occupational stress (ATH 04071)	211
J. Siegrist, H. Matschinger, P. Cremer and D. Seidel (F.R.G.)	
Factor analysis of plasma lipoprotein components (ATH 04076)	219
I. Aursnes, P. Smith, E.N. Christiansen and K. Berg (Norway)	
Variations in lipoproteins, hormones and blood glucose during the early acute phase of myocardial infarction (ATH 04077)	225
F. Mainard, P. Ozanne and Y. Madec (France)	
Influence of etofibrate on low density lipoprotein metabolism (ATH 04078)	233
J.J. Series, M.J. Caslake, C. Kilday, A. Cruickshank, T. Demant, C.J. Packard and J. Shepherd (U.K.)	
High density lipoprotein (HDL) subfractions in cardiovascular patients with low levels of HDL-cholesterol. Influence of hypertriglyceridaemia on subfraction concentration and composition (ATH 04079)	241
M.L. Hong, R.W. James, B. Grab and D. Pometta (Switzerland)	
Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia (ATH 04080)	249
M.-R. Taskinen and E.A. Nikkilä (Finland)	
Lipoprotein uptake in primary cell cultures of rabbit atherosclerotic lesions. A fluorescence microscopic and flow cytometric study (ATH 04081)	257
O. Jaakkola, O.-P. Kallionиеми and T. Nikkari (Finland)	
Effects of melatonin on genetic hypercholesterolemia in rats (ATH 04066)	269
H. Aoyama, N. Mori and W. Mori (Japan)	
<i>Letters to the Editor</i>	
A question concerning apo B-48 (ATH 04072)	273
P. Avogaro, G. Cazzolato and G. Bittolò Bon	
A question concerning apo B-48. A reply to the letter by P. Avogaro, G. Cazzolato and B. Bittolò Bon (ATH 04073)	275
M. Poapst and K.U.G. Steiner	
<i>Erratum</i>	
<i>Announcements</i>	
<i>Author Index (Vol. 69)</i>	
<i>Subject Index (Vol. 69)</i>	

